Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'Maison F, Grammond P, Barnett M, Lechner-Scott J, Alroughani R, Trojano M, Lugaresi A, Granella F, Pucci E, Vucic S; MSBase Study Group.
Spelman T, et al. Among authors: burke t.
Eur J Neurol. 2016 Apr;23(4):729-36. doi: 10.1111/ene.12929. Epub 2016 Jan 19.
Eur J Neurol. 2016.
PMID: 26782663